BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.
April 14, 2025
Announcement no. 10
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR A PUBLIC OFFER OF THE SECURITIES DESCRIBED HEREIN NOR IS IT AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE “UNITED STATES”)) OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.
THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY UNDER ANY APPLICABLE SECURITIES LAWS OF ANY OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, OR IN ANY OTHER JURISDICTION, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY SUCH STATE OR OTHER JURISDICTION (AS THE CASE MAY BE).
BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.
Copenhagen, Denmark, April 14, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that the Board of Directors has decided to carry out a private placement of up to 25,000,000 new shares at market price (the “Offering”).
In connection with the publication of its 2023 Annual Report on April 4, 2024, BioPorto announced plans to raise approximately USD 20 million by issuing new shares in 2024 and 2025, to support the growth of its business. On June 18, 2024, BioPorto successfully completed the first funding round, an oversubscribed direct issuance of 50 million new shares with gross proceeds of DKK 81.4 million (company announcement 14/2024).
The Offering announced today is the next step in the execution of the financing strategy to raise DKK 55 million (USD 8.3 million*) in the first half of 2025. The Company will continue its financing strategy, raising capital or exploring alternatives to limit shareholder dilution. The net proceeds from the Offering are to be applied to finance the clinical trials to seek FDA clearance for ProNephro AKI™ (NGAL) for adult use in the United States, increase sales and marketing activities for the Company’s current product line, including the NGAL Test ™, as well as general corporate purposes.
Indications from existing shareholders, new investors, and the management team
The Company has received advanced indications from existing large shareholders, new professional investors, board members and the management team to subscribe for the full Offering.
Key Terms of the Offering
The Offering is made as a cash share capital increase directed at a limited group of shareholders, institutional and financial investors without pre-emptive subscription rights for the Company’s existing shareholders in accordance with the authorization stipulated in Article 17b and 17c of BioPorto’s Articles of Association.
The Offering comprises up to 25,000,000 new shares of nominally DKK 1 each, equivalent to 5.8% of BioPorto’s registered share capital prior to the share capital increase.
The subscription price is DKK 1.3402, which was the closing price of BioPorto shares traded on Nasdaq Copenhagen A/S on April 11, 2025. The expected total gross proceeds from the share issue will amount to DKK 33,505,000 at full subscription.
The new shares will carry the same rights as existing shares in BioPorto. The new shares will be negotiable instruments, and no restrictions will apply to their transferability. No shares, including the new shares, carry or will carry any special rights. The new shares shall be registered in the name of the holder through VP Securities A/S (Euronext Securities Copenhagen). The rights relating to the new shares, including voting rights and dividend rights, will apply from the time when the capital increase is registered with the Danish Business Authority. In the event of oversubscription, the new shares will be allocated by the Board of Directors.
The Offering will be carried out as a directed issue to eligible institutional and professional investors in Denmark pursuant to applicable exemptions from the obligation to publish a prospectus under the Prospectus Regulation (EU) 2017/1129. The Offering will be made without pre-emption rights for BioPorto’s existing shareholders.
Expected timeline
The subscription period will commence immediately and close at short notice. The results of the Offering will be announced as soon as practicably possible thereafter, expected later today.
The share capital increase will be registered with the Danish Business Authority as soon as the subscription amount is fully paid, currently expected to be on Friday, April 25, 2025.
The new shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen A/S under the Company’s permanent ISIN-code (DK0011048619) as soon as possible thereafter, currently expected to be no later than April 30, 2025. The admission to trading and official listing of the new shares is subject to the Offering not being withdrawn prior to the settlement of the Offering and the Company making an announcement to that effect.
*) DKK/USD Exchange Rate app. 6.6
To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.
Investor Relations Contacts
Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@bioporto.com, C: +45 26368918
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
Forward looking statement disclaimer
Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings, including its Annual Report for 2024, with the Danish Financial Supervisory Authority, particularly under the heading “Risk Factors”.
Attachment
